SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Dauntless who wrote (2786)3/17/1998 12:48:00 PM
From: Linda Kaplan  Read Replies (2) | Respond to of 7041
 
Dauntless,

Okay, peace... except I still have a few quibbles. Your saying "long a competitor" puts Zonagen on an equal plane with Vivus. Zonagen isn't a competitor until it has an approved product. Pfizer might have an almost approved product, so they might be considered a competitor to Vivus, but Zonagen isn't there yet.

Collaborative seems like a wrong word, too, suggesting an active partnership between the two companies. Perhaps one would enhance the market for the other, but that's really not a collaboration, is it?

Linda



To: Dauntless who wrote (2786)3/17/1998 1:06:00 PM
From: clochard  Respond to of 7041
 
"and therefore their individual successes will bolster the entire market(a rising tide lifts all boats)"

A rising tide has helped Zonagen a lot. We will soon see if the storm caused by Viagra, the lawsuits, and the general lack of anything tangible will sink this poor little tugboat.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News